Variability in Intravenous Immunoglobulin G Regimens for Autoimmune Neuromuscular Disorders

被引:18
作者
Broyles, Randy [1 ]
Rodden, Linda [2 ]
Riley, Patty [3 ]
Berger, Melvin [2 ]
机构
[1] BioRx, Operations, Cincinnati, OH 45242 USA
[2] CSL Behring LLC, Immunol Res & Dev, King Of Prussia, PA USA
[3] CSL Behring LLC, King Of Prussia, PA USA
关键词
intravenous immunoglobulin G; autoimmune neuromuscular disorders; autoimmune inflammatory diseases; chronic inflammatory demyelinating polyneuropathy; myasthenia gravis; INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; RANDOMIZED CONTROLLED-TRIAL; PERIPHERAL-NERVE-SOCIETY; JOINT TASK-FORCE; MYASTHENIA-GRAVIS; NEUROLOGICAL-SOCIETIES; EUROPEAN-FEDERATION; CLINICAL-TRIAL; OPEN-LABEL;
D O I
10.3810/pgm.2013.03.2619
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: We reviewed the intravenous immunoglobulin G (IVIG) dispensing records of a specialty pharmacy to characterize the IVIG treatment regimens used for chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenia gravis (MG) in community practice. Methods: Anonymized records were selected based on International Classification of Diseases, Ninth Revision (ICD-9) codes and IVIG treatment for > 1 month. Each patient's immunoglobulin G (IgG) dose per infusion (mg/kg/dose) was multiplied by the number of doses per month (30.5 days divided by the dosing interval in days) to yield the total monthly dose (mg/kg/month). Data were analyzed and summarized using descriptive statistics. Results: Forty-six patients (median age, 56.5 years; range, 8-86 years) fulfilled the inclusion criteria. Thirty-one patients with CIDP received IgG at 7-to 92-day intervals (mean [standard deviation (SD)], 28 [16] days). The mean (SD) IgG dose was 75 (60) g/dose, equivalent to 866 (623) mg/kg/dose and 1145 (778) mg/kg/month. Six patients with stable MG received IVIG or subcutaneous IgG at 3.5-to 61-day intervals (28 [20] days) at a mean (SD) IgG dose of 39 (15) g/dose, equivalent to 405 (108) mg/kg/dose and 783 (680) mg/kg/month. Nine patients with MG with acute exacerbations received IgG at 7-to 42-day intervals (22 [12] days) at a mean (SD) dose of 40 (21) g/dose, equivalent to 403 (172) mg/kg/dose and 641 (288) mg/kg/month. One patient with CIDP and 4 patients with MG were treated with weekly subcutaneous IgG injections. Conclusion: Although patients with CIDP and MG are treated with mean total monthly IgG doses similar to those approved by the US Food and Drug Administration, the individual doses and intervals vary considerably, suggesting that physicians may be adjusting IgG dosing according to each patient's clinical condition and treatment response. Further study is necessary to determine the criteria used to adjust IgG treatment regimens and whether these adjustments optimize clinical outcomes while limiting overall costs.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 34 条
[1]  
[Anonymous], 2012, GAMM LIQ PACK INS
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]  
[Anonymous], 2012, J PERIPHER NERV SYST, V17, P229
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]  
[Anonymous], 2010, GAM C PACK INS
[6]   A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma® [J].
Berger, Melvin .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :628-633
[7]   Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose [J].
Berger, Melvin .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 11 (06) :532-538
[8]   Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies [J].
Berger, Melvin ;
Rojavin, Mikhail ;
Kiessling, Peter ;
Zenker, Othmar .
CLINICAL IMMUNOLOGY, 2011, 139 (02) :133-141
[9]   The Construction of a Pharmacokinetic Model to Describe Intravenous and Subcutaneous Supplementation of IgG in Patients with Primary Immunodeficiency (PID) [J].
Bexon, M. ;
Rojavin, M. ;
Jolles, S. ;
Ellis, S. ;
Sawyer, J. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) :AB16-AB16
[10]   Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia [J].
Björkander, J ;
Nikoskelainen, J ;
Leibl, H ;
Lanbeck, P ;
Wallvik, J ;
Lumio, JT ;
Braconier, JH ;
Pavlova, BG ;
Birthistle, K ;
Engl, W ;
Walter, S ;
Ehrlich, HJ .
VOX SANGUINIS, 2006, 90 (04) :286-293